Company intelligence / Profile preview

Biotalys

Ownership: Private
Employees: ~70
Development stage: Preclinical

Overview

Biotalys develops a new generation of protein-based biocontrol solutions for sustainable crop protection. Its lead products have demonstrated high efficacy against major fungal pathogens like Botrytis cinerea and powdery mildew in field trials on fruits and vegetables. The company’s proprietary AGROBODY™ platform enables discovery of novel proteins with targeted modes of action. As of mid–2025, its first products are awaiting regulatory approval before commercial launch.

Therapeutic areas: Other
Modalities: Protein-based biocontrolsRecombinant protein
Industry: Agriculture & AgTech

Drug pipeline

5 assets

EVOCA

NDA

Indications: Botrytis, Powdery mildew

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Biotalys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotalys.

Explore the full profile